We’re thrilled to announce a new strategic alliance between ExSyn, Exim-Indis and simABs, a leading EU-based biologics manufacturer known for its patented continuous flow technology in antibody production.
ExSyn and Exim-Indis will now represent simABs in the Indian and the U.S. markets respectively —bringing their innovative, high-quality antibodies to researchers, biotech companies, and healthcare providers.
simAbs: Smart Integrated Manufacturing of ATMP’s and Biologics
simAbs provides the full range of services and support for biologics development and GMP manufacturing, specializing in sustainable biomanufacturing technologies.
For more details, please visit:
https://www.simabs.com/
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
Methyl-2-Methoxy-5-Sulfamoyl Benzoate (MSMB) is a sulfur containing organic building block acting as a chemical intermediate. MSMB contains ester and sulfamoyl functional groups, which make it useful as a pharmaceutical and fine-chemical intermediate.
The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to zero.
Imidazolidinyl urea is a widely used antimicrobial preservative in the cosmetic and personal care industry. It is a formaldehyde-releasing compound that effectively inhibits the growth of bacteria, yeast, and molds, thereby extending the shelf life of formulations. Due to its broad-spectrum efficacy and cost-effectiveness, it is commonly used in rinse-off and leave-on products within regulated concentration limits.